Macrophage Activation Syndrome Clinical Trial
Official title:
Assessment of Macrophage Activation syndromE in STill's Disease: Retrospective Chart Analysis of Patient HistorY, Symptom Resolution and Treatment Characteristics
Assessment of Macrophage activation syndrome in STill's disease: retrospective chart analysis of patient History, Symptom resolution and Treatment characteristics
This is an observational, retrospective cohort study on the treatment utilization and outcomes of Macrophage Activation Syndrome (MAS) refractory to glucocorticoids (GC) in patients with Still's disease. The study will be conducted entirely through medical chart abstraction; all data will be taken from the patient's medical record, with no additional assessments. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03721809 -
Characterization of the Inflammatory Profile of Patients With Macrophage Activation Syndrome Secondary to Bacterial Sepsis
|
N/A | |
Active, not recruiting |
NCT02780583 -
Treatment of Macrophage Activation Syndrome (MAS) With Anakinra
|
Phase 1 | |
Active, not recruiting |
NCT01966367 -
CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT01095146 -
New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome
|
N/A | |
Recruiting |
NCT06339177 -
Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
|
||
Recruiting |
NCT02569463 -
Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome(MAS)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05137496 -
Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome
|
Phase 3 | |
Active, not recruiting |
NCT03827343 -
Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
|
||
Recruiting |
NCT05611710 -
Anakinra in Dengue With Hyperinflammation ( AnaDen )
|
Phase 2 | |
Completed |
NCT03311854 -
A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
|
Phase 2 | |
Recruiting |
NCT05001737 -
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
|
Phase 3 | |
Completed |
NCT03332225 -
A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis
|
Phase 2 | |
Completed |
NCT04339712 -
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction
|
Phase 2 |